[1] Sonneveld M J, Janssen H L A. Individualising endpoints in chronic HBV treatment: HBsAg loss and beyond[J]. J Hepatol, 2026, 84(4): 823-828.
[2] Dongelmans E J, Patmore L A, Lim S G, et al. HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER)[J/OL]. Gut, 2025-11-05.https://pubmed.ncbi.nlm.nih.gov/41198171/
[3] Anderson M, Holzmayer V, Stec M, et al. Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: considerations for new and existing therapies[J]. J Hepatol, 2024, 81(1): e24-e25.
[4] Vittal A, Sharma D, Hu A, et al. Systematic review with meta-analysis: the impact of functional cure on clinical outcomes in patients with chronic hepatitis B[J]. Aliment Pharmacol Ther, 2022, 55: 8-25.
[5] Dusheiko G, Agarwal K, Maini M K. New approaches to chronic hepatitis B[J]. N Engl J Med. 2023,388:55-69.
[6] Chen J, Ji D, Jia J, et al. Functional cure with new antiviral therapy for hepatitis B virus: a systematic review and meta-analysis[J]. Hepatol Int, 2025, 19: 773-795.
[7] Hirode G, Choi H S, Chen C H, et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multi-center, multi-ethnic cohort (RETRACT-B study)[J]. Gastroenterology, 2022, 162(3): 757-771.
[8] Loggi E, Gitto S, Gabrielli F, et al. Virological treatment monitoring for chronic hepatitis B[J]. Viruses, 2022, 14(7): 1376.
[9] Brakenhoff S M, de Knegt R J, van Campenhout M J, et al. End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients[J]. J Microbiol Immunol Infect, 2023, 56(1): 31-39.
[10] Wu J F, Tai C S, Chang K C, et al. Predictors of functional cure of chronic hepatitis B virus infection: a long-term follow-up study[J]. Clin Gastroenterol Hepatol, 2025, 23(4): 583-590.e3.
[11] Lin H Y, Hsin K H, Liu C J, et al. Hepatitis B core-related antigen kinetics predict spontaneous HBeAg seroclearance in chronic hepatitis B patients[J]. J Gastroenterol, 2025.
[12] Enomoto M, Wong G L H, Huang R, et al. Evolving strategies in HBV management: insights from updated international guidelines[J]. Hepatol Res, 2026, 56(5): e70205.
[13] Wong G L H, Gane E, Lok A S F. How to achieve functional cure of HBV: stopping NUCs, adding interferon or new drug development?[J]. J Hepatol, 2022, 76: 1249-1262.
[14] Wübbolding M, Lopez Alfonso J C, Lin C Y, et al. Pilot study using machine learning to identify immune profiles for the prediction of early virological relapse after stopping nucleos(t)ide analogues in HBeAg-negative CHB[J]. Hepatol Commun, 2020, 5: 97-111.
[15] World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection[M]. Geneva: World Health Organization, 2024. |
